Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medeor Therapeutics, Inc.

https://medeortx.com/index.php

Latest From Medeor Therapeutics, Inc.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

Regenerative Medicine Review Pathway

Pipeline Watch: Phase III Starts For Molidustat, Tecentriq And Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Venture Funding Deals: Semma, Arcus Raise $100m-Plus For Cancer, Diabetes Therapies

Semma's $114m Series B round and a $107m Series C for Arcus top November's list of biopharmaceutical venture capital deals. Forty Seven, Medeor and Tricida also closed sizeable rounds.

StartUps and SMEs Financing

Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace

Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register